Published On : July 2026
Infectious disease IVD products are purchased by a wide range of institutional buyers, and each buyer type tends to prioritize a different combination of test menu, throughput, and turnaround time. Hospitals need rapid results for acutely ill patients, diagnostic laboratory chains optimize for batch efficiency across large sample volumes, and public health agencies weigh population-level screening value as much as individual patient outcomes. This buyer diversity connects directly to the customer segment breakdown of the IVD market introduced in the market overview, where hospitals and healthcare providers represent the single largest buyer group.
This page looks at each major end-user category in turn, then examines how those buyers interact with the physical laboratory settings, central, hospital-based, reference, and point-of-care, where testing is actually performed.
This diversity of institutional buyers is closely linked to where testing physically happens. A public health agency running a national screening campaign, for instance, may rely heavily on point-of-care testing formats deployed in community settings, while a large hospital network processes the bulk of its testing volume through a central or hospital-based laboratory. Understanding both the buyer and the setting together gives a more complete picture of how testing demand actually flows through the healthcare system than looking at either dimension in isolation.
Hospitals and healthcare providers represent the largest institutional buyer category for infectious disease IVD products, driven by the volume of acute-care testing required across emergency departments, inpatient wards, and outpatient clinics. Hospital laboratories prioritize rapid turnaround above almost every other purchasing criterion, since a delayed result can directly affect a critically ill patient's treatment pathway.
This urgency shapes purchasing behavior in a specific way. Hospitals frequently maintain both a central hospital laboratory for routine batch testing and a smaller point-of-care testing footprint embedded directly in high-acuity units such as the emergency department or intensive care unit, allowing the most time-sensitive tests to bypass the central lab entirely. Larger hospital networks also increasingly consolidate purchasing decisions at the network level rather than the individual facility level, which is gradually shifting negotiating leverage toward centralized procurement teams.
Hospital laboratory operations are also being reshaped by broader healthcare consolidation trends. As independent hospitals increasingly join larger multi-facility health systems, laboratory services are often restructured around a hub-and-spoke model, where a flagship facility's central laboratory handles complex or lower-volume testing referred from smaller affiliated hospitals, while each individual facility retains only the point-of-care and basic testing capability needed for its own emergency and inpatient services.
This restructuring has meaningful implications for how manufacturers approach hospital accounts, since a single purchasing conversation with a hospital network's laboratory leadership can now influence testing technology decisions across dozens of individual facilities rather than just one, a shift that rewards suppliers capable of supporting standardized testing protocols across a distributed network.
Diagnostic laboratory chains operate at a fundamentally different scale than individual hospital laboratories, running centralized, high-throughput testing operations that serve multiple client hospitals, physician offices, and direct-to-consumer channels simultaneously. Because these chains process extremely high sample volumes, they tend to favor fully automated platforms with minimal manual handling, and purchasing decisions are typically driven by cost per test and instrument uptime as much as by raw analytical performance.
Regulatory compliance is a persistent operational concern for this buyer segment, since diagnostic laboratory chains often operate across multiple countries or states, each with its own accreditation and certification requirements. Navigating country-specific regulatory requirements for laboratories is therefore a core operational competency for multi-site diagnostic chains, not simply a compliance formality.
Diagnostic laboratory chains have also expanded their reach in recent years through direct-to-consumer testing channels, allowing patients to order certain infectious disease tests without a traditional physician referral in some jurisdictions. This channel has grown alongside broader consumer comfort with self-directed health testing, though it remains a smaller share of overall chain volume compared with traditional physician-ordered and hospital-referred testing.
For manufacturers, this channel expansion means diagnostic laboratory chains increasingly need testing platforms that can support both traditional high-throughput clinical workflows and newer, more consumer-facing service models, a dual requirement that is gradually influencing how these chains evaluate new platform investments.
Public health agencies represent a distinct buyer category driven by population-level screening mandates rather than individual patient care decisions. Government tuberculosis and HIV screening programs, outbreak surveillance initiatives, and vaccination-adjacent testing campaigns all generate demand that can be lumpy and difficult to forecast using standard commercial sales patterns, since a single outbreak response can generate a testing volume spike that dwarfs routine annual demand.
Blood banks and screening centers occupy a related but distinct niche, focused specifically on transfusion-safety testing to prevent transmission of infectious agents through donated blood products. This use case demands extremely high sensitivity, since a false negative carries direct patient-safety consequences, and blood banks are typically among the most conservative adopters of new testing technology as a result, preferring extensively validated methods over newer but less-proven alternatives.
Public health testing programs frequently need to scale rapidly in response to a specific event, whether a disease outbreak, a new government screening mandate, or a multilateral funding initiative, and this creates a structurally different demand pattern than the steady, predictable ordering volumes typical of hospital or diagnostic laboratory buyers. Suppliers serving this segment often need to maintain surge production capacity that would be difficult to justify for routine commercial demand alone.
Blood banks, by contrast, tend to operate on a much steadier and more predictable testing cadence tied directly to donation volumes, which gives this buyer segment a more stable, if smaller, demand profile relative to the more variable public health agency segment.
Research institutes and academic laboratories represent a smaller but strategically important buyer segment, driving demand for both established testing platforms used in epidemiological studies and newer, higher-specification instruments used in assay development and pathogen characterization work. Because much of this demand is grant-funded rather than driven by routine clinical care needs, purchasing cycles can be less predictable, often clustering around funding cycles and specific research initiatives.
For manufacturers, this segment is disproportionately valuable as an early-adoption channel, since academic researchers frequently publish validation data that influences downstream clinical adoption decisions, effectively functioning as an informal proving ground for newer testing technologies before they reach mainstream hospital and diagnostic laboratory buyers.
Research funding structures also shape which testing technologies research institutes tend to adopt first. Academic laboratories with access to substantial grant funding are often early adopters of newer, higher-specification molecular and multiplex platforms, while institutions with more constrained budgets may continue relying on established, lower-cost immunoassay methods for routine research testing needs. This variation makes the research and academic segment more heterogeneous in its purchasing behavior than most other end-user categories covered on this page.
Central laboratories are built around scale, running large batches of samples through highly automated platforms to achieve the lowest possible cost per test. Hospital-based laboratories sit physically within or adjacent to the care facility, prioritizing turnaround time over the pure batch economics that central laboratories optimize for.
Reference laboratories occupy a specialized niche, typically receiving samples referred from smaller facilities that lack the equipment or expertise for a particular esoteric or low-volume test, and are valued for depth of test menu rather than routine throughput.
Point-of-care and decentralized testing environments represent the newest and fastest-growing setting, built around point-of-care testing kits that bring results directly to the location where the patient is being seen rather than requiring sample transport to a fixed laboratory. Each setting therefore serves a distinct role in the overall testing ecosystem, and most health systems rely on some combination of all four rather than consolidating entirely around one model.
The boundaries between these four laboratory settings are also becoming less rigid than they once were. Some larger reference laboratories now operate point-of-care testing programs on behalf of client hospitals that lack in-house capacity for certain esoteric tests, effectively blending the reference and point-of-care models within a single service relationship. Similarly, some hospital laboratories have begun operating satellite point-of-care testing stations directly within outpatient clinics, extending their institutional footprint beyond the traditional central laboratory building itself.
This blending reflects a broader trend across the healthcare system: testing infrastructure is increasingly organized around where clinical need arises rather than around the traditional boundaries between laboratory setting types.
For manufacturers and channel strategists, this convergence means that product design and service support increasingly need to travel across setting boundaries rather than being built for a single environment. A platform originally designed for a central laboratory workflow, for instance, may need a compact, simplified variant suited to a satellite point-of-care station if it is to capture demand across an institution's full testing footprint.
Who are the primary institutional buyers of infectious disease IVD products?
The primary institutional buyers are hospitals and healthcare providers, diagnostic laboratory chains, public health agencies, research institutes and academic labs, and blood banks and screening centers, each with distinct purchasing priorities.
What is the difference between central laboratory and point-of-care testing?
Central laboratory testing is optimized for high-volume batch processing at the lowest cost per test, typically with longer turnaround, while point-of-care testing delivers results directly at or near the patient, prioritizing speed over batch efficiency.
How do public health agencies typically procure diagnostic tests?
Public health agencies generally procure through government tenders and multilateral screening programs tied to specific disease-control initiatives, which can create demand patterns that spike sharply around outbreak or screening campaigns rather than following steady commercial ordering cycles.
Why are research institutes an important end-user segment for IVD manufacturers?
Research institutes and academic labs often serve as an early-adoption channel, generating validation data through published research that influences downstream clinical adoption decisions across hospital and diagnostic laboratory buyers.